Other languages Bausch + Lomb Corporation

Equities

Market Closed - Nyse Other stock markets 21:00:02 02/05/2024 BST			5-day change	1st Jan Change
13.86 ^USD	+0.87%		-6.10%	-18.76%

05-02	RBC Capital Reviews Bausch + Lomb's Q1 Results	MT
05-02	Deutsche Bank Adjusts Bausch + Lomb Price Target to $14 From $18, Maintains Hold Rating	MT

RBC Capital Reviews Bausch + Lomb's Q1 Results	05-02
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	05-01
Bausch + Lomb Q1 Loss Widens, Revenue Increases	05-01
Bausch + Lomb Q1 Net Loss Widens, But Revenue Higher; Raises 2024 Revenue Growth Guidance	05-01
Bausch + Lomb Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01
Bausch + Lomb Says Study Shows Improvements in Dry Eyes With Nutritional Supplement	04-25
Bausch + Lomb Corporation Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	04-25
RBC Previews Bausch Health's Q1, Trims Target to US$11	04-23
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	04-12
Bausch + Lomb Corporation Announces Board Changes	02-28
Deutsche Bank on Bausch + Lomb's Q4	02-22
Bausch + Lomb's Likely to Face Market-Related Risks From Spin, RBC Says	02-22
RBC Raises Bausch + Lomb Target to US$20, Reiterates Outperform, After Q4	02-22
Sector Update: Health Care Stocks Mixed in Late Afternoon	02-21
Needham Reviews Bausch + Lomb's Q4	02-21
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	02-21
Sector Update: Health Care	02-21
Bausch + Lomb Offers Upbeat 2024 Revenue Outlook as Fourth-Quarter Results Exceed Views	02-21
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday	02-21
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Ahead of Fed Meeting Minutes	02-21

No results for this search